Key facts
- This page summarizes Jack E. Stover's Form 4 filing for Onconova Therapeutics, Inc. (TRAW).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 19 Aug 2022, 17:10.
Jack E. Stover - 18 Aug 2022 Form 4 Insider Report for Onconova Therapeutics, Inc. (TRAW)
- Reporting relationship
- Director
- Issuer ticker
- TRAW
- Reported as of
- 18 Aug 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 19 Aug 2022, 17:10:11 UTC
- Prior SEC filing
- 23 Aug 2022
- Next SEC filing
- 14 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Guerin, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jack E. Stover filed Form 4 for Onconova Therapeutics, Inc. (TRAW) on 19 Aug 2022.
Change
- Previous filing in this sequence was filed on 23 Aug 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ONTX
transaction
Derivative
Stock Option (right to purchase)
Award
- Transaction value
- $0
- Shares
- +66,468
- Change %
- Price
- $0.000000
- Shares after
- 66,468
- Date
- 18 Aug 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 66,468
- Exercise price
- $1.26
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
These options vest 100% on the first anniversary of the grant date.